Company profile
Pyxis Oncology, Inc.
NASDAQ: PYXS · Healthcare · Biotechnology
#591 of 1,420 Healthcare companies by revenue30th-percentile growth
EA Score
28DFH 34DQ 15GM —SS 46
v0.1 · 55/100 weight · provisional
↑ market scale, balance-sheet leverage · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$13.9M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$79.6M
Employees
56
as of 2026-08-14
Market cap
$190.7M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$13.9M$13.9M2025
Net income-$79.6M-$79.6M2025
Operating income-$84.4M-$84.4M2025
Total assets$91.5M$91.5M2025
Liabilities$38.1M$38.1M2025
Equity$53.4M$53.4M2025
Revenue by segment
Filed disclosures · FY2025
By product
Milestone Revenue100%
By geography
Not disclosed.
The read
What is Pyxis Oncology, Inc.’s revenue?
Pyxis Oncology, Inc. booked $13.9M in FY2025 revenue, contracting 14% year over year — slower than 70% of Healthcare companies we track, at a -574.5% net margin.
Peers · Healthcare
Opus Genetics, Inc.39DArbutus Biopharma Corp61CHealthcare Triangle, Inc.40DBiotricity, Inc.——CV Sciences, Inc.56CHyperfine, Inc.44DNeighbors
Suffolk →Key facts
CEOThomas Civik
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: PYXS
Employees56
IPO date2021-10-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.